Literature DB >> 10330262

Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11.

R Raut1, J L Rouleau, C Blais, H Gosselin, G Molinaro, M G Sirois, Y Lepage, P Crine, A Adam.   

Abstract

The respective role of angiotensin-converting enzyme (ACE) and neutral endopeptidase 24.11 (NEP) in the degradation of bradykinin (BK) has been studied in the infarcted and hypertrophied rat heart. Myocardial infarction (MI) was induced in rats by left descendant coronary artery ligature. Animals were killed, and hearts were sampled 1, 4, and 35 days post-MI. BK metabolism was assessed by incubating synthetic BK with heart membranes from sham hearts and infarcted (scar) and noninfarcted regions of infarcted hearts. The half-life (t1/2) of BK showed significant differences among the three types of tissue at 4 days [sham heart (114 +/- 7 s) > noninfarcted region (85 +/- 4 s) > infarcted region (28 +/- 2 s)] and 35 days post-MI [sham heart (143 +/- 6 s) = noninfarcted region (137 +/- 9 s) > infarcted region (55 +/- 4 s)]. No difference was observed at 1 day post-MI. The participation of ACE and NEP in the metabolism of BK was defined by preincubation of the membrane preparations with enalaprilat, an ACE inhibitor, and omapatrilat, a vasopeptidase inhibitor that acts by combined inhibition of NEP and ACE. Enalaprilat significantly prevented the rapid degradation of BK in every tissue type and at every sampling time. Moreover, omapatrilat significantly increased the t1/2 of BK compared with enalaprilat in every tissue type and at every sampling time. These results demonstrate that experimental MI followed by left ventricular dysfunction significantly modifies the metabolism of exogenous BK by heart membranes. ACE and NEP participate in the degradation of BK since both enalaprilat and omapatrilat have potentiating effects on the t1/2 of BK.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10330262     DOI: 10.1152/ajpheart.1999.276.5.H1769

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

Review 1.  Omapatrilat: a new tool for understanding metabolism of bradykinin at the endothelium level.

Authors:  M J Dumoulin; D Lamontagne; G Molinaro; A Adam
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

2.  The cardiovascular actions of omapatrilat in spontaneously hypertensive rats.

Authors:  Y Dong; H Zhou; E Shaffer; N Atamas; W C Liao; C Wei
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

3.  Kallidin-like peptide mediates the cardioprotective effect of the ACE inhibitor captopril against ischaemic reperfusion injury of rat heart.

Authors:  Xiuxin Liu; Martina Lukasova; Radka Zubakova; Sabina Lewicka; Ulrich Hilgenfeldt
Journal:  Br J Pharmacol       Date:  2006-06-12       Impact factor: 8.739

4.  Bradykinin potentiation by ACE inhibitors: a matter of metabolism.

Authors:  Beril Tom; Andreas Dendorfer; René de Vries; Pramod R Saxena; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

5.  Comparative effects of a vasopeptidase inhibitor vs. an angiotensin converting enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure.

Authors:  Nathalie Lapointe; James N Tsoporis; Thomas G Parker; Charles Blais; Albert Adam; Dominique Rouleau; Graham Slaughter; Robert Clément; Christian E Deschepper; Jean L Rouleau
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

6.  Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.

Authors:  Wei-Chi Liao; Ole Vesterqvist; Carol Delaney; Mohammed Jemal; Irene Ferreira; Neville Ford; Brian Swanson; Howard Uderman
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.